Brain-derived neurotrophic factor alterations and cognitive decline in schizophrenia:Implications for early intervention  

作　　者：Uchenna E Okpete Haewon Byeon 

机构地区：[1]Department of Digital Anti-aging Healthcare(BK21),Inje University,Gimhae 50834,South Korea

出　　处：《World Journal of Psychiatry》2025年第1期189-193,共5页世界精神病学杂志（英文）

基　　金：Supported by Basic Science Research Program Through the National Research Foundation of Korea(NRF)Funded By the Ministry of Education,No.NRF-RS-2023-00237287.

摘　　要：This manuscript explores the recent study by Cui et al which assessed the interplay between inflammatory cytokines and brain-derived neurotrophic factor(BDNF)levels in first-episode schizophrenia patients.The study revealed that higher levels of interleukin-6 and tumor necrosis factor-αcorrelated with reduced BDNF levels and poorer cognitive performance.Schizophrenia is a severe psy-chiatric disorder impacting approximately 1%of the global population,charac-terized by positive symptoms(hallucinations and delusions),negative symptoms(diminished motivation and cognitive impairments)and disorganized thoughts and behaviors.Emerging research highlights the role of BDNF as a potential biomarker for early diagnosis and therapeutic targeting.The findings from Cui et al’s study suggest that targeting neuroinflammation and enhancing BDNF levels may improve cognitive outcomes.Effective treatment approaches involve a com-bination of pharmacological and non-pharmacological interventions tailored to individual patient needs.Hence,monitoring cognitive and neuroinflammatory markers is essential for improving patient outcomes and quality of life.Conse-quently,this manuscript highlights the need for an integrated approach to schizo-phrenia management,considering both clinical symptoms and underlying neuro-biological changes.

关 键 词：SCHIZOPHRENIA Cognitive impairment Neuroinflammatory markers Brain-derived neurotrophic factor INTERLEUKIN Personalized treatment 

分 类 号：R749.4[医药卫生—神经病学与精神病学]